Fig. 3: Oncoprint representation of SNV or CNV alterations in the entire FN-RMS cohort (35 samples, 17 patients). | npj Precision Oncology

Fig. 3: Oncoprint representation of SNV or CNV alterations in the entire FN-RMS cohort (35 samples, 17 patients).

From: Sequential genomic analysis using a multisample/multiplatform approach to better define rhabdomyosarcoma progression and relapse

Fig. 3

a Oncoprint representation of SNV or CNV in a subset of FN-RMS with detectable genetic alterations. Frequency of gene alterations (left column, %) is applied to the whole sample cohort per patient (n = 35 tumors, 17 patients). Samples from same patients are grouped together and color-coded (shades of gray) based on primary tumor, local recurrence, or distant metastasis. Left side plot groups the patients without newly acquired major alterations at relapse and right side plot depicts patients with clonal evolution. Bar chart at the top panel shows the number of alterations in each sample highlighting the mutational gain in the relapse. One patient lacking mutations in this oncoprint is further detailed in Supplementary Figure 1. b Lollipop plot of SMARCA2 SNV mutations found in 4 relapsed FN-RMS, depicted in association to corresponding protein domains. Lower panel showing histology of primary/relapsed FN-RMS with E710K mutation (H&E, A, E), and immunohistochemistry positivity for desmin (B, F) and myogenin (C, G) and loss of SMARCA2 protein expression (D, H).

Back to article page